sanofi beyfortus news - Search News

Sanofi, BEYFORTUS

GlobalData on MSN · 4d

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, targeting both private healthcare providers and the Centers for Disease Control and Prevention's Vaccines for Children programme,

Sanofi Shipping BEYFORTUS® In US To Help Protect Babies Against RSV Disease New Manufacturing Line Approved By FDA

Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the

Business Insider · 4d

Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts

Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the

Reuters on MSN · 4d

Sanofi, AstraZeneca win approval for RSV therapy manufacturing line

Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory

The Pharma Letter · 4d

Sanofi shipping RSV jab Beyfortus in USA

French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the USA to private healthcare providers and to the Centers for Disease Control and Prevention.

TBR News Media1d

Local doctors recommend flu and covid shots cosome time in the next few weeks

With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...

Zacks.com on MSN1d

Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...

ENDPOINTS NEWS1d

BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

BioPharma Dive4d

Sanofi readies to meet US demand for RSV antibody

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

1d

Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results